JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech’s 2024 sales surged 342% YoY, driven by a Takeda payment.
Chinese Biotech Ascentage Pharma’s Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
Where Today's News Shapes Tomorrow
